Bryan Johnson Compared to Other Public Longevity Figures

By
Published Updated Last reviewed
Clinical medical image for celebrities bryan johnson: Bryan Johnson Compared to Other Public Longevity Figures

At a glance

  • Protocol scope: 200+ daily interventions spanning rapamycin, acarbose, NAD+ precursors, testosterone optimization, and multiple peptides including BPC-157 and GHK-Cu
  • Disclosure level: Full ingredient lists, dosing schedules, and longitudinal biomarker panels published openly through Project Blueprint
  • Key pivot: Johnson publicly discontinued rapamycin in 2024 after epigenetic biological-age clock data raised concerns
  • Comparison set: Peter Attia, Andrew Huberman, Tony Robbins, and Dave Asprey have each discussed longevity compounds publicly, but with varying degrees of specificity and clinical documentation
  • Clinical takeaway: Transparency about failures matters as much as successes; Johnson's rapamycin discontinuation is a rare example of public protocol correction

The public longevity disclosure spectrum

Not all celebrity health disclosures are created equal. Some public figures confirm specific medications with dosing details. Others hint at general categories. A few, like Bryan Johnson, publish everything.

Johnson has confirmed use of rapamycin (sirolimus), acarbose, NMN (nicotinamide mononucleotide), NAD+ IV infusions, testosterone optimization, and peptides including BPC-157, GHK-Cu, and hexarelin as part of his Project Blueprint protocol. He has also confirmed discontinuing rapamycin in 2024 after his biological-age clocks showed concerning trends, a decision he discussed publicly on social media and in interviews.

This level of disclosure is unprecedented. To understand why it matters clinically, the HealthRX Medical Team compared Johnson's approach to other public longevity figures across three dimensions: what they disclosed, how much clinical data they provided, and whether they reported negative outcomes.

Bryan Johnson vs. other public longevity figures

Peter Attia, MD has publicly discussed his personal use of rapamycin and has been one of the most vocal physician advocates for its off-label longevity application. Attia confirmed rapamycin use in his book Outlive (2023) and in multiple podcast appearances. He provides clinical reasoning but does not publish personal biomarker panels the way Johnson does. Attia's disclosures carry extra weight because he is a practicing physician, but his protocol specifics remain less granular than Blueprint.

Andrew Huberman, PhD has discussed peptides, testosterone optimization, and various supplements on his podcast, though his personal protocol disclosures have been less systematic. Huberman has confirmed personal use of certain compounds in passing but has not published a structured protocol document or longitudinal biomarker data. Much of what is attributed to him as "his protocol" is speculated by fans based on podcast content rather than confirmed by a formal disclosure.

Dave Asprey has publicly confirmed using rapamycin, NAD+ infusions, and stem cell therapies as part of his stated goal to live to 180. Asprey's disclosures, shared through his books and the Bulletproof brand, tend to emphasize personal benefit without the failure-reporting that characterizes Johnson's approach.

Tony Robbins co-authored Life Force (2022) and has publicly discussed peptide therapies, stem cell treatments, and regenerative medicine. His disclosures are tied to advocacy for specific clinics and therapies. Robbins has not published personal biomarker data or a structured daily protocol comparable to Blueprint.

The clinical compounds: what the evidence actually shows

The HealthRX Medical Team reviewed the primary evidence behind Johnson's confirmed compounds. Public fascination with the protocol is high, but the clinical data behind each agent varies enormously.

Rapamycin (sirolimus)

Rapamycin inhibits mTOR (mechanistic target of rapamycin), a kinase central to cell growth, autophagy, and immune regulation. In mouse models, rapamycin has extended median lifespan by 9 to 14% even when started late in life. The Interventions Testing Program (ITP) has replicated this across multiple sites.

In humans, the evidence is far more limited. A 2014 trial by Mannick et al. showed that low-dose mTOR inhibition improved immune function in older adults, but no completed human trial has demonstrated lifespan extension. Off-label use typically ranges from 1 to 6 mg weekly, cycled.

Johnson's decision to stop rapamycin in 2024 is clinically significant. He reported that epigenetic clock measurements (likely DunedinPACE or similar methylation-based assays) showed his biological aging rate was not improving or was worsening. The HealthRX Medical Team notes that this kind of public course correction is rare and valuable: it demonstrates that biomarker-guided decision-making can lead to discontinuation, not just escalation.

Side effects of rapamycin include immunosuppression, impaired wound healing, hyperlipidemia, and oral ulcers. The FDA label carries a black-box warning for immunosuppression in transplant patients, though longevity advocates argue that weekly low-dose use differs meaningfully from daily high-dose transplant regimens.

Acarbose

Acarbose is an alpha-glucosidase inhibitor approved by the FDA for type 2 diabetes. It slows carbohydrate digestion, blunting postprandial glucose spikes. The ITP found that acarbose extended median lifespan in male mice by 22% (with a smaller effect in females), making it one of the strongest lifespan results in the ITP's history.

In humans, acarbose is well-studied for glycemic control. The STOP-NIDDM trial showed it reduced progression from impaired glucose tolerance to type 2 diabetes by 25%. Johnson uses it as a glucose-flattening agent. Typical longevity doses range from 25 to 50 mg before meals. GI side effects (bloating, flatulence, diarrhea) are common and dose-limiting.

NAD+ precursors (NMN and IV NAD+)

Johnson has confirmed using both NMN (nicotinamide mononucleotide) orally and NAD+ via IV infusion. NAD+ is a coenzyme critical to mitochondrial function, DNA repair, and sirtuin activity. Levels decline with age.

NMN supplementation raises NAD+ levels in human blood, as shown in a 2022 clinical trial published in Science. Whether raising NAD+ translates to clinical longevity outcomes in humans remains unproven. Typical oral NMN doses in self-experimenters range from 250 mg to 1 g daily. IV NAD+ infusions bypass oral bioavailability but are expensive ($500 to $1,500 per session) and lack controlled trial data for longevity endpoints.

The HealthRX Medical Team cautions that NAD+ precursor supplementation sits in a gray zone: the biochemistry is sound, animal data is promising, but human lifespan or healthspan trials have not been completed.

Testosterone and hormone optimization

Johnson has publicly reported monitoring and optimizing testosterone levels as part of Blueprint. His protocol treats testosterone not in isolation but as one variable within a broader endocrine panel. He has disclosed total and free testosterone values alongside SHBG, estradiol, and DHEA-S.

Testosterone replacement in men with clinically low levels is associated with improved bone density, lean mass, and sexual function per the Testosterone Trials (TTrials). The Endocrine Society guidelines recommend treatment for men with confirmed hypogonadism and symptoms, not for age-related decline alone.

Peptides: BPC-157, GHK-Cu, hexarelin

Johnson has confirmed using multiple peptides. BPC-157 (body protection compound-157) is a synthetic peptide derived from gastric juice that has shown wound-healing and anti-inflammatory effects in animal studies. No peer-reviewed human clinical trial has been published for BPC-157 as of this writing. GHK-Cu is a copper peptide with demonstrated wound-healing and collagen-stimulating properties in cell and animal models. Hexarelin is a growth hormone secretagogue. All three are used off-label and are not FDA-approved for longevity indications.

What the disclosure pattern reveals

The HealthRX Medical Team identifies three tiers of public longevity disclosure:

Tier 1 (Full protocol publication): Bryan Johnson stands alone here. Blueprint publishes compound names, doses, timing, supplier information, biomarker data over time, and protocol changes including discontinuations. This level of transparency allows independent clinical evaluation.

Tier 2 (Confirmed use with clinical framing): Peter Attia and Dave Asprey have both named specific compounds and provided clinical reasoning, though without Johnson's longitudinal data publication. Attia's medical background adds a layer of clinical credibility to his disclosures.

Tier 3 (Partial or indirect disclosure): Andrew Huberman and Tony Robbins have discussed longevity compounds publicly but without structured protocol documentation. Fan communities often fill gaps with speculation, creating a distorted picture of what these figures actually use.

The clinical danger lives in the gap between Tier 1 and Tier 3. When a public figure mentions a compound without dosing, monitoring, or context, followers may self-prescribe without the safeguards that make Johnson's approach at least internally consistent.

The HealthRX Medical Team take

Johnson's protocol is not a template for self-medication. It is a case study in what maximum-transparency self-experimentation looks like. The HealthRX Medical Team highlights several lessons from comparing his approach to other public figures:

Failure reporting matters. Johnson discontinuing rapamycin publicly is more useful to the field than any number of testimonials about compounds "working." The willingness to report negative biomarker trends, and to change course based on them, is exactly what distinguishes evidence-guided experimentation from wellness marketing.

Most longevity compounds lack human lifespan data. Rapamycin, acarbose, and NAD+ precursors all have strong preclinical signals. None has a completed randomized controlled trial showing human lifespan extension. The TAME trial (Targeting Aging with Metformin) is the closest thing to a longevity RCT in progress, and it studies metformin rather than any of Johnson's primary compounds.

Celebrity disclosure is not medical advice. Even Johnson's unusually detailed protocol is n=1. His genetics, baseline health, and monitoring resources are not generalizable. The HealthRX Medical Team recommends that anyone considering longevity pharmacology work with a physician who can order baseline labs, monitor for side effects, and adjust protocols based on individual response, not based on what a public figure reports on social media.

Frequently asked questions

›
›
›
›
›

References